C
Christiane Yoakim
Researcher at Boehringer Ingelheim
Publications - 105
Citations - 2841
Christiane Yoakim is an academic researcher from Boehringer Ingelheim. The author has contributed to research in topics: Thromboxane & Protease. The author has an hindex of 32, co-authored 105 publications receiving 2725 citations. Previous affiliations of Christiane Yoakim include Merck & Co. & Université de Montréal.
Papers
More filters
Journal ArticleDOI
Dimethylboron bromide and diphenylboron bromide: cleavage of acetals and ketals
TL;DR: In this paper, the authors reactite des boranes du titre vis-a-vis du clivage d'acetals cycliques et acycliques, de cetals, de perhydropyrannyl-and perhydrofuryl ethers, de glycosides de methyle, d'acetonides and d'ethers de -methoxymethyle, -methyl-methoxyethoxyl methyl and methylthiomethyle
Journal ArticleDOI
Discovery of BI 224436, a Noncatalytic Site Integrase Inhibitor (NCINI) of HIV-1.
Lee Fader,Eric Malenfant,Mathieu Parisien,Rebekah J. Carson,François Bilodeau,Serge Landry,Marc Pesant,Christian Brochu,Sébastien Morin,Catherine Chabot,Ted Halmos,Yves Bousquet,Murray D. Bailey,Stephen H. Kawai,René Coulombe,Steven R. LaPlante,Araz Jakalian,Punit Bhardwaj,Dominik Wernic,Patricia Schroeder,Ma’an Amad,Paul J. Edwards,Michel Garneau,Jianmin Duan,Michael G. Cordingley,Richard Bethell,Stephen W. Mason,Michael Bös,Pierre R. Bonneau,Marc-André Poupart,Anne-Marie Faucher,Bruno Simoneau,Craig Fenwick,Christiane Yoakim,Youla S. Tsantrizos +34 more
TL;DR: An assay recapitulating the 3' processing activity of HIV-1 integrase (IN) was used to screen the Boehringer Ingelheim compound collection, leading to the discovery of compound 26 (BI 224436), the first NCINI to advance into a phase Ia clinical trial.
Journal ArticleDOI
Distinct Effects of Two HIV-1 Capsid Assembly Inhibitor Families That Bind the Same Site within the N-Terminal Domain of the Viral CA Protein
Christopher T. Lemke,Steve Titolo,Uta K. von Schwedler,Nathalie Goudreau,Jean‐François Mercier,Elizabeth Wardrop,Faucher Anne-Marie,René Coulombe,Soma S. R. Banik,Lee Fader,Alexandre Gagnon,Stephen H. Kawai,Jean Rancourt,Martin Tremblay,Christiane Yoakim,Bruno Simoneau,Jacques Archambault,Wesley I. Sundquist,Stephen W. Mason +18 more
TL;DR: The development of an in vitro capsid assembly assay based on the association of CA-NC subunits on immobilized oligonucleotides is described and demonstrated that inhibitors that bind within the same site on CA can have distinct binding modes and mechanisms of action.
Patent
Non-nucleoside reverse transcriptase inhibitors
Patrick Deroy,Anne-Marie Faucher,Alexandre Gagnon,Serge Landry,Sébastien Morin,Jeffrey O'meara,Bruno Simoneau,Bounkham Thavonekham,Christiane Yoakim +8 more
TL;DR: In this article, the authors defined compounds of formula (I) wherein Ar, X, R1, R2, R3 and R4 are as defined herein and pharmaceutical compositions thereof useful, either alone or in combination with other therapeutic agents as reverse transcriptase inhibitors against wild type and single or double mutant strains of HIV for the treatment or prophylaxis of HIV infection.
Journal ArticleDOI
Preclinical Profile of BI 224436, a Novel HIV-1 Non-Catalytic-Site Integrase Inhibitor
Craig Fenwick,Ma’an Amad,Murray D. Bailey,Richard Bethell,Michael Bös,Pierre R. Bonneau,Michael G. Cordingley,René Coulombe,Jianmin Duan,Paul J. Edwards,Lee Fader,Anne-Marie Faucher,Michel Garneau,Araz Jakalian,Stephen H. Kawai,Louie Lamorte,Steven R. LaPlante,Laibin Luo,Steve Mason,Marc-André Poupart,Nathalie Rioux,Patricia Schroeder,Bruno Simoneau,Sonia Tremblay,Youla S. Tsantrizos,Myriam Witvrouw,Christiane Yoakim +26 more
TL;DR: BI 224436 has drug-like in vitro absorption, distribution, metabolism, and excretion properties, including Caco-2 cell permeability, solubility, and low cytochrome P450 inhibition, and has an additive effect in combination with most approved antiretrovirals, including INSTIs.